Aa
diet questions
Are some fats allowed for liver health diet? I'm wondering about avacados, does anyone have a link to good diet info? Thank you. I'm still awaiting my 1/15 doc visit. (scared) whatever happened w/ the drug Alinia? M
News on alinia
Alinia - http://www.sptimes.com/2008/01/04/Business/Drug_s_promise_revita.shtml
another link:
Nitazoxanide - alinia
One of the most interesting studies released at AASLD was a small study that was conducted in Egypt using nitazoxanide (Alinia) to treat hepatitis C. Nitazoxanide is a medicine approved by the FDA for the treatment of diarrhea caused by Cryptosporidium and Giardia. In this study, 96 treatment naïve HCV genotype 4 patients were randomized into three groups:
1. 40 patients who received pegylated interferon plus ribavirin (control arm) for 48 weeks.
2. 28 patients who received nitazoxanide for 12 weeks followed by 36 weeks of nitazoxanide plus pegylated interferon (dual therapy),
3. 28 patients who received nitazoxanide followed by 36 weeks of nitazoxanide plus pegylated interferon plus ribavirin (triple therapy),
An additional 24 HCV patients who had previously received interferon treatment were randomized: 12 weeks of nitazoxanide followed by either the dual regimen (12 patients) or the triple therapy (12 patients).
Note: nitazoxanide was given as one 500 mg pill twice daily; pegylated interferon was given as an 180 mcg injection once a week, and ribavirin was weight based 1000/12000 mg daily.
At 12 weeks post treatment it was found that 79% of patients in the triple therapy group achieved an SVR compared to 43% who achieved an SVR in the group receiving the combination of pegylated interferon plus ribavirin. In the group of previously treated patients the SVR was 25% in the group who received the triple therapy compared to 8 percent in the group who received the dual therapy. The speaker commented that the mechanism of action is not really understood and that larger studies are needed to confirm these findings and to understand the mechanism of action. These results are almost too good to be true, but hopefully the results from this study can be replicated in a well designed study with a larger patient population of people with HCV genotype 1.
http://www.hepcaustralia.com.au/treatment-news/drugs-in-development-results.html
Alinia - http://www.sptimes.com/2008/01/04/Business/Drug_s_promise_revita.shtml
another link:
Nitazoxanide - alinia
One of the most interesting studies released at AASLD was a small study that was conducted in Egypt using nitazoxanide (Alinia) to treat hepatitis C. Nitazoxanide is a medicine approved by the FDA for the treatment of diarrhea caused by Cryptosporidium and Giardia. In this study, 96 treatment naïve HCV genotype 4 patients were randomized into three groups:
1. 40 patients who received pegylated interferon plus ribavirin (control arm) for 48 weeks.
2. 28 patients who received nitazoxanide for 12 weeks followed by 36 weeks of nitazoxanide plus pegylated interferon (dual therapy),
3. 28 patients who received nitazoxanide followed by 36 weeks of nitazoxanide plus pegylated interferon plus ribavirin (triple therapy),
An additional 24 HCV patients who had previously received interferon treatment were randomized: 12 weeks of nitazoxanide followed by either the dual regimen (12 patients) or the triple therapy (12 patients).
Note: nitazoxanide was given as one 500 mg pill twice daily; pegylated interferon was given as an 180 mcg injection once a week, and ribavirin was weight based 1000/12000 mg daily.
At 12 weeks post treatment it was found that 79% of patients in the triple therapy group achieved an SVR compared to 43% who achieved an SVR in the group receiving the combination of pegylated interferon plus ribavirin. In the group of previously treated patients the SVR was 25% in the group who received the triple therapy compared to 8 percent in the group who received the dual therapy. The speaker commented that the mechanism of action is not really understood and that larger studies are needed to confirm these findings and to understand the mechanism of action. These results are almost too good to be true, but hopefully the results from this study can be replicated in a well designed study with a larger patient population of people with HCV genotype 1.
http://www.hepcaustralia.com.au/treatment-news/drugs-in-development-results.html
Have an Answer?
You are reading content posted in the Hepatitis Social Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
